MeTC7
规格
| Cas Number | 1817841-22-7 |
| 规格或纯度 | ≥98% |
| 纯度 | ≥98% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 16.67 mg/mL (26.95 mM; ultrasonic and warming and heat to 60°C) |
| 过滤标签 | VD/VDR,Vitamin D Related/Nuclear Receptor |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | MeTC7 是一种维生素 D 受体（VDR）拮抗剂。MeTC7 具有强效的 VDR 抑制活性，其 IC 50 值为 2.9 μM。MeTC7 具有良好的抗肿瘤效果。 |
| 英文描述 |
MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC 50 value of 2.9 μM. MeTC7 shows good antitumor effects In Vitro MeTC7 (compound 5) shows potent VDR inhibition activity with an IC 50 value of 2.9 μM. MeTC7 disrupts the VDR-Ligand-binding domain in Silico. MeTC7 (250 nM; 18 h) suppresses RXRα and Importin-4 expressions in the ovarian cancer cell-line. MeTC7 (250 nM; 18 h) inhibits the viability of ovarian cancer cells and induces PARP1 cleavage. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: 2008 cells Concentration: 250 nM Incubation Time: 18, 12 h Result: Reduced the expression of RXR-α, Importin-4 and increased cleaved PARP1 expression in 2008 cells. Cell Viability AssayCell Line: SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines Concentration: 0, 0.25, 0.5, 0.75, 1.0, 1.25 μM Incubation Time: 24 h Result: Reduced the viability of SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines. In Vivo MeTC7 (compound 5) (i.p.; 10 mg/kg) reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 10 mg/kg Administration: IP Result: Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells. Inhibited the growth of neuroblastoma cells and Xenografts. Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma. Form:Solid IC50& Target:IC50: 2.9 μM (VDR) |